ENTX - Entera Bio to Present Phase 1 Data from First-in-Class PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024 | Benzinga
JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that it has been selected to present data for its investigational program EB612 at the Endocrine Society ENDO 2024 Annual Meeting which will be held on June 1-4, 2024 in Boston, Massachusetts.
The EB612 program is being developed by Entera to provide the first oral PTH(1-34) tablet peptide replacement therapy for patients suffering from hypoparathyroidism. Hypoparathyroidism is characterized by deficient PTH production, hypocalcemia and hyperphosphatemia. Standard treatments include several daily administrations of high dose oral calcium supplements and calcitriol (or analogs), which are often associated with ectopic calcification, including nephrocalcinosis and renal failure. Late stage investigational PTH replacement treatments include TransCon PTH (palopegteriparatide) by Ascendis Pharma A/S and eneboparatide (AZP-3601) by Amolyt Pharma (pending acquisition by AstraZeneca). Both these modalities require patients to administer injections every day.
The data from this Phase 1 study include PK and early PD results from the application of a new generation of Entera's N-Tab™ technology platform with an unmodified PTH(1-34) peptide. One of the objectives of this study was to test the new platform's ability to reduce the frequency of daily administration of EB612. Entera previously published positive Phase 2a study results in 19 hypoparathyroid patients using a QID regimen (Fraser, JBMR 2021).
Abstract Title: Phase 1 Study Results Of EB612, A First-in-Class Oral PTH(1-34) Analog For The Treatment Of Hypoparathyroidism
Presentation Number: SAT-758
Presentation Type: Late-Breaking Poster Presentations: Day 1
Session: Poster Session P106
Session Date/Time: Saturday, June 1, 2024, 12:15 pm – 1:45 pm
The abstract can be found on the ENDO 2024 website: https://www.abstractsonline.com/pp8/#!/11016/presentation/9825
About Entera Bio
Entera is a clinical stage company focused on developing oral peptide or protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary ...